MSLN and ovarian carcinoma: In phase I of a clinical trial (NCT03198546), one patient with recurrent stage III ovarian cancer received two intraperitoneal infusions of anti-mesothelin CAR-T cells engineered to secrete IL-7 and CCL19 (anti-MSLN-7x19 CAR-T).